These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16268200)

  • 1. Cost effectiveness and cost-savings opportunities associated with human growth hormone.
    Manag Care Interface; 2005; Suppl():14-5. PubMed ID: 16268200
    [No Abstract]   [Full Text] [Related]  

  • 2. Human growth hormone treatment in adults: balancing economics and ethics.
    Cook D; Owens G; Jacobs M
    Am J Manag Care; 2004 Oct; 10(13 Suppl):S417-9. PubMed ID: 15622872
    [No Abstract]   [Full Text] [Related]  

  • 3. Which children should receive growth hormone treatment. Cost-benefit analysis is the key.
    Kelnar CJ
    Arch Dis Child; 2000 Aug; 83(2):176-8. PubMed ID: 10950748
    [No Abstract]   [Full Text] [Related]  

  • 4. Economic implications of growth hormone use in patients with short bowel syndrome.
    Migliaccio-Walle K; Caro JJ; Möller J
    Curr Med Res Opin; 2006 Oct; 22(10):2055-63. PubMed ID: 17022865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GH in idiopathic short stature. Is growth hormone treatment ethical or cost effective?
    Wales JK
    BMJ; 2011 Apr; 342():d2142. PubMed ID: 21467109
    [No Abstract]   [Full Text] [Related]  

  • 6. Developing a rational approach for the use of growth hormone in nonpediatric patients.
    Cook D; Owens G
    Am J Manag Care; 2004 Oct; 10(13 Suppl):S436-40. PubMed ID: 15622876
    [No Abstract]   [Full Text] [Related]  

  • 7. New treatment available for AIDS cachexia.
    Hoyt G
    Surviv News (Atlanta Ga); 2003; ():7. PubMed ID: 14666919
    [No Abstract]   [Full Text] [Related]  

  • 8. When Medi-Cal says 'no' to Serostim.
    Kline-Capelle L
    Posit Living; 2002; 11(5):34, 44. PubMed ID: 12422825
    [No Abstract]   [Full Text] [Related]  

  • 9. Current efforts in standards development. United States.
    Power EJ
    Med Care; 1996 Dec; 34(12 Suppl):DS200-3; discussion DS204-7. PubMed ID: 8969327
    [No Abstract]   [Full Text] [Related]  

  • 10. Determinants of short stature and the response to growth hormone therapy.
    Dunger DB
    Horm Res; 2009 Apr; 71 Suppl 2():2-4. PubMed ID: 19407490
    [No Abstract]   [Full Text] [Related]  

  • 11. Growth hormone therapy for short stature: is the benefit worth the burden?
    Allen DB
    Pediatrics; 2006 Jul; 118(1):343-8. PubMed ID: 16818584
    [No Abstract]   [Full Text] [Related]  

  • 12. PHARMAC's updated guidelines for cost-effectiveness analyses, with new discount rate.
    Grocott R; Metcalfe S
    N Z Med J; 2007 Jul; 120(1258):U2641. PubMed ID: 17653257
    [No Abstract]   [Full Text] [Related]  

  • 13. [What is a cost-effectiveness analysis?].
    Müller-Bohn T
    Med Monatsschr Pharm; 2004 Sep; 27(9):301-3. PubMed ID: 15490616
    [No Abstract]   [Full Text] [Related]  

  • 14. The short of it: more short children are being given growth hormone in the hope that an extra inch will protect their supposedly fragile psyches. But research suggests that their height is a problem less for them than for us.
    Hall SS
    N Y Times Mag; 2005 Oct; ():54-9. PubMed ID: 16733876
    [No Abstract]   [Full Text] [Related]  

  • 15. Perspective and pharmacoeconomic analyses.
    Kozma CM
    Manag Care Interface; 2005 Dec; 18(12):53-4. PubMed ID: 16405225
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacoeconomics: historical perspective.
    Bootman JL; McGhan WF; Townsend RJ
    Ann Pharmacother; 2006 Mar; 40(3):518-9. PubMed ID: 16478813
    [No Abstract]   [Full Text] [Related]  

  • 17. How can pharmacoeconomics be more useful?
    Kozma CM
    Manag Care Interface; 2005 May; 18(5):25-6. PubMed ID: 15941186
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
    Bartkó G; Fehér L
    Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Debate on the use of growth hormone in the treatment of children with idiopathic short stature (ISS) (Pro and Con).
    Rogol AD; Wit JM
    Pediatr Endocrinol Rev; 2007 Mar; 4(3):226-7. PubMed ID: 17551485
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
    Weintraub WS
    J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.